Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2.
暂无分享,去创建一个
S. Larson | N. Cheung | P. Zanzonico | Hong-fen Guo | S. Modak | Yukang Lin | D. Axworthy | L. Theodore | Y. Zuo | J. Sanderson | S. Wilbert | John Chung | Sibylle Wilbert | Yuting Zuo
[1] C. Meares,et al. Pretargeting: general principles; October 10-12, 1996. , 1997, Cancer.
[2] M. Delgado,et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. , 2002, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.
[3] W. Oyen,et al. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate. , 1999, Cancer research.
[4] Habib Zaidi,et al. Therapeutic Applications of Monte Carlo Calculations in Nuclear Medicine , 2002 .
[5] K. D. Hardman,et al. Single-chain antigen-binding proteins. , 1988, Science.
[6] D. Goldenberg. Advancing role of radiolabeled antibodies in the therapy of cancer , 2003, Cancer Immunology, Immunotherapy.
[7] Y. Lin,et al. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. , 2000, Cancer research.
[8] M. Cremonesi,et al. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. , 1998, British Journal of Cancer.
[9] P. Beaumier,et al. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[10] F. Fazio,et al. Monoclonal antibody pretargetting techniques for tumour localization: the avidin‐biotin system , 1991, Nuclear medicine communications.
[11] M. Little,et al. Single-chain antibody streptavidin fusions: tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen. , 1995, Human antibodies and hybridomas.
[12] N. Cheung,et al. Monoclonal antibody-based therapy of neuroblastoma. , 2001, Hematology/oncology clinics of North America.
[13] P. Zanzonico,et al. Computational methods in internal radiation dosimetry , 2002 .
[14] R C Boston,et al. Conversational SAAM--an interactive program for kinetic analysis of biological systems. , 1981, Computer programs in biomedicine.
[15] George Sgouros,et al. Murine S factors for liver, spleen, and kidney. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] G. Denardo,et al. Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] R. Reisfeld,et al. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[18] T. Waldmann,et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. , 2002, Blood.
[19] M. Goris,et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] N. Cheung,et al. Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice. , 1986, Journal of the National Cancer Institute.
[21] P. Abrams,et al. Radioimmunotherapy of Cancer , 2000 .
[22] R. Bruccoleri,et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[23] D. Axworthy,et al. Evolution of a Pretarget Radioimmunotherapeutic Regimen , 2000 .
[24] Damon L. Meyer,et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. , 2001, Blood.
[25] B. L. Bauer,et al. Gangliosides: the relevance of current research to neurosurgery. , 1991, Journal of neurosurgery.
[26] James J. Vincent,et al. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. , 2001, Cancer research.
[27] L. Kostakoglu,et al. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses. , 1996, Nuclear medicine and biology.
[28] T. Waldmann,et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[29] P. Caliceti,et al. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. , 2001, Cancer biotherapy & radiopharmaceuticals.
[30] M G Stabin,et al. Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[31] N. Cheung,et al. Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy. , 2003, Hybridoma and hybridomics.
[32] D. Fisher,et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. , 2000, Cancer biotherapy & radiopharmaceuticals.
[33] F. Virzi,et al. Investigations of avidin and biotin for imaging applications. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] N. Cheung,et al. Anti-idiotypic antibody as the surrogate antigen for cloning scFv and its fusion proteins. , 2002, Hybridoma and hybridomics.
[35] N. Cheung,et al. Targeting of ganglioside GD2 monoclonal antibody to neuroblastoma. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[36] P. Beaumier,et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[37] N. Cheung,et al. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. , 1985, Cancer research.